| Literature DB >> 31583948 |
Roman P Simon1, Martin Winter1, Carola Kleiner1, Robert Ries1, Gisela Schnapp2, Annekatrin Heimann2, Jun Li3, Ljiljana Zuvela-Jelaska3, Tom Bretschneider1, Andreas H Luippold1, Wolfgang Reindl1, Daniel Bischoff1, Frank H Büttner1.
Abstract
Comprehensive and unbiased detection methods are a prerequisite for high-throughput screening (HTS) campaigns within drug discovery research. Label-free matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) has been introduced as an HTS-compatible readout for biochemical test systems to support the drug discovery process. So far, reported HTS applications were based on surface-modified systems or proof-of-concept studies. We present the utilization of a MALDI-TOF-based screening platform to identify inhibitors of human cyclic GMP-AMP synthase (cGAS), a mediator of innate immune response whose aberration has been causally correlated to a number of inflammatory disorders. In this context, the development and validation of a MALDI-TOF-based activity assay is reported to demonstrate fast, robust, and accurate detection of chemical cGAS inhibition by direct quantification of the physiological reaction product cyclic GMP-ATP (cGAMP). Results from a screen of a diverse library of more than 1 million small molecules in 1536-well format against the catalytic cGAS activity are presented with excellent assay performance and data quality. Identified hits were qualified in dose-response experiments and confirmed by RapidFire-MS measurements. Conclusively, the presented data provide the first proof of applicability of direct automated MALDI-TOF MS as a readout strategy for large-scale drug discovery HTS campaigns.Entities:
Keywords: MALDI-TOF; cGAS; drug discovery; high-throughput screening; mass spectrometry
Mesh:
Substances:
Year: 2019 PMID: 31583948 DOI: 10.1177/2472555219880185
Source DB: PubMed Journal: SLAS Discov ISSN: 2472-5552 Impact factor: 3.341